Professor, Faculty of Bioscience and Applied Chemistry Department of Chemical Science and Technology, Hosei University (Concurrent) Professor, Hosei University Graduate School Graduate School of Science and Engineering.
RESEARCH AREAS
– Manufacturing technology (mechanical, electrical/electronic, chemical engineering) / Transfer phenomena and unit operations / Chemical Engineering Materials Properties/Transfer Operation/Unit Operation.
– Manufacturing technology (mechanical, electrical/electronic, chemical engineering) / Applied biofunctional and bioprocess engineering / Bio-Function/Bioprocesses.
RESEARCH HISTORY
– Apr, 2010 – Mar, 2013: Professor, Department of Human Environmental Science, School of Engineering, Shonan Institute of Technology.
– Apr, 2004 – Mar, 2010: Professor, Department of Human Environmental Science, School of Engineering, Shonan Institute of Technology.
– Apr, 1999 – Mar, 2004: Associate Professor, Department of Materials Science, School of Engineering, Shonan Institute of Technology.
– Jul, 1991 – Mar, 1999: Assistant Professor, Department of Biochemical Systems Engineering, Faculty of Computer Science and Systems Engineering, Kyushu Institute of Technology.
– Apr, 1994 – Mar, 1999: Lecturer, Department of Chemical Engineering, National Kita-Kyushu College of Industrial and Technology.
– Jul, 1991 – Mar, 1999: Assistant Professor, Department of Biochemical Systems Engineering, Faculty of Computer Science and Systems Engineering, Kyushu Institute of Technology.
– Apr, 1980 – Aug, 1986: Visiting scholar, Kidney Center, Kitasato University Hospital.
– Apr, 1980 – Aug, 1986: Department of Research, Medical Institute Zenjinkai.
– Apr, 1980 – Aug, 1986: Visiting scholar, Kidney Center, Kitasato University Hospital.
– Apr, 1980 – Aug, 1986: Manager, Department of Research, Medical Institute Zenjinkai.
– Apr, 1980 – Aug, 1986: Research Assistant, Department of Applied Chemistry, School of Science and Engineering, Waseda University.
ABBSTRACT
Title: Current status of online hemodiafiltration in Japan
～ the role of alpha1-microglobulin ～
Hashimoto Clinic Kenji Sakurai
At the end of 2021 there were 349,700 dialysis patients, while in 1968, the year JSDT was founded, there were only 215. Therefore, there were 1600 fold increase in the number of patients during this 53 year-period. Diabetic nephropathy became the main causative disease of ESRD since 1998 and CGN had been the leading cause until then.
HDF patients had been increasing year by year since 2012. At the end of 2021, 50.5% of the total number of dialysis patients were receiving HDF. 70.5% of HDF patients are receiving online HDF, and 28.3% are receiving I-HDF. Over 95% of on-line HDF in Japan are performed with the pre-dilution mode.
We have reported that in dialysis patients, Restless Legs Syndrome can be cured by continuous OL-HDF with a reduction rate of α1-microglobulin (A1M) of 40%, and that high-efficiency removal of A1M is also highly effective for the treatment of impaired joint mobility, arthralgia and other conditions associated with dialysis amyloidosis.
We could not determine why enhanced removal of A1M improves the symptoms associated with complications of dialysis therapy. However, in 2018, Kim proposed the following mechanism: These complications of dialysis therapy are caused by chronic microinflammation, and inflammatory cytokines, reactive oxygen species and other substances act on one another at the sites of inflammation; and the antioxidant A1M acts at these sites to eliminate reactive oxygen species and break the vicious cycle of inflammation, resulting in the resolution of symptoms. Since then, A1M has been understood not only as a biomarker of the removal efficiency of large molecules, but also as a functional molecule that plays an important role in dialysis therapy.
